Anti-Human IL-17 (Bimekizumab) (I-2130-1.0mg)

Interleukin 17 (IL-17) is a pro-inflammatory cytokine crucial to host defense, tissue repair, pathogenesis of inflammatory disease, and progression of cancer1. IL-17 signaling is also critical for protection against fungal and bacterial infection2. There are six pro-inflammatory cytokines (IL-17A-F) produced by Th17 cells3. IL-17A and IL-17F share ~50% structural homology4 as well as overlapping biological functions in chronic inflammation and adaptive immune defense from bacterial and fungal infection5. Additionally, they are coexpressed in immune- inflammatory diseases5. IL-17A and IL-17F drive pathogenesis in psoriasis5 and are both found in lesional skin and inflamed synovium from patients with psoriatic arthritis4. Since dual neutralization of IL-17A and IL-17F results in lower expression of inflammation-linked genes and cytokines 4 and because targeting the IL-17 pathway has clinical efficacy5, an antibody therapeutic designed to potently and selectively neutralize both IL-17A and IL-17F is desirable. Bimekizumab is a humanized monoclonoal antibody designed to bind at a similar site on both IL-17A and IL-17F, allowing for dual inhibition5. Bimekizumab has been approved for use in the treatment of plaque psoriasis6, psoriatic arthritis7, and axial spondyloarthritis8.